Implementation and extended evaluation of the Euroimmun Anti-1

SARS-CoV-2 IgG assay and its contribution to the United Kingdom's 2

COVID-19 public health response. 3

4

5	Ashley David Otter ^{1,2*} , Abbie Bown ¹ , Silvia D'Arcangelo ^{1,2} , Daniel Bailey ¹ , Amanda
6	Semper ³ , Jacqueline Hewson ² , Matthew Catton ¹ , Prem Perumal ¹ , Angela Sweed ¹ ,
7	Jessica Jones ³ , Heli Harvala ⁴ , Abigail Lamikanra ⁴ , Maria Zambon ⁵ , Nick Andrews ⁵ ,
8	Heather Whitaker ⁵ , Ezra Linley ⁶ , Alexander J Mentzer ^{7,8} , Donal Skelly ^{8,9,10} , Julian C.
9	Knight ⁷ , Paul Klenerman ⁹ , PHE Porton Euroimmun testing group ^{11†} , Gayatri
10	Amirthalingam ⁵ , Stephen Taylor ¹² , Cathy Rowe ^{11,2} , Richard Vipond ^{1,3} , Tim Brooks* ³ .
11	
12	* - corresponding authors: ashley.otter@phe.gov.uk, tim.brooks@phe.gov.uk
13	+ - Complete list of authors listed in the appendix 1
14	
15	1 – Diagnostic Support, National Infection Service, Public Health England, Porton, SP4 0JG
16	2 – SARS-CoV-2 serosurveillance laboratory, National Infection Service, Public Health England, Porton, SP4 0JG
16 17	2 – SARS-CoV-2 serosurveillance laboratory, National Infection Service, Public Health England, Porton, SP4 0JG 3 – Rare and Imported Pathogens Laboratory, Public Health England, Porton, SP4 0JG
17	3 – Rare and Imported Pathogens Laboratory, Public Health England, Porton, SP4 0JG
17 18	3 – Rare and Imported Pathogens Laboratory, Public Health England, Porton, SP4 0JG 4 – NHS Blood and Transfusion, Microbiology Services, Colindale, UK
17 18 19	 3 – Rare and Imported Pathogens Laboratory, Public Health England, Porton, SP4 0JG 4 – NHS Blood and Transfusion, Microbiology Services, Colindale, UK 5 – Public Health England, Colindale, NW9 5EQ
17 18 19 20	 3 – Rare and Imported Pathogens Laboratory, Public Health England, Porton, SP4 0JG 4 – NHS Blood and Transfusion, Microbiology Services, Colindale, UK 5 – Public Health England, Colindale, NW9 5EQ 6 – Seroepidemiology Unit, Public Health England, Manchester, M13 9WZ
17 18 19 20 21	 3 – Rare and Imported Pathogens Laboratory, Public Health England, Porton, SP4 0JG 4 – NHS Blood and Transfusion, Microbiology Services, Colindale, UK 5 – Public Health England, Colindale, NW9 5EQ 6 – Seroepidemiology Unit, Public Health England, Manchester, M13 9WZ 7 – Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
17 18 19 20 21 22	 3 – Rare and Imported Pathogens Laboratory, Public Health England, Porton, SP4 0JG 4 – NHS Blood and Transfusion, Microbiology Services, Colindale, UK 5 – Public Health England, Colindale, NW9 5EQ 6 – Seroepidemiology Unit, Public Health England, Manchester, M13 9WZ 7 – Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK 8 – Oxford University Hospitals NHS Foundation Trust, Oxford, UK
17 18 19 20 21 22 23	 3 - Rare and Imported Pathogens Laboratory, Public Health England, Porton, SP4 0JG 4 - NHS Blood and Transfusion, Microbiology Services, Colindale, UK 5 - Public Health England, Colindale, NW9 5EQ 6 - Seroepidemiology Unit, Public Health England, Manchester, M13 9WZ 7 - Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK 8 - Oxford University Hospitals NHS Foundation Trust, Oxford, UK 9 - Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, UK
 17 18 19 20 21 22 23 24 	 3 - Rare and Imported Pathogens Laboratory, Public Health England, Porton, SP4 0JG 4 - NHS Blood and Transfusion, Microbiology Services, Colindale, UK 5 - Public Health England, Colindale, NW9 5EQ 6 - Seroepidemiology Unit, Public Health England, Manchester, M13 9WZ 7 - Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK 8 - Oxford University Hospitals NHS Foundation Trust, Oxford, UK 9 - Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, UK 10 - Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

Page 1 of 36

27 1. Abstract

28 In March 2020, the Rare and Imported Pathogens Laboratory at Public Health 29 England, Porton Down, was tasked by the Department of Health and Social Care with 30 setting up a national surveillance laboratory facility to study SARS-CoV-2 antibody 31 responses and population-level sero-surveillance in response to the growing SARS-32 CoV-2 outbreak. In the following 12 months, the laboratory tested more than 160,000 33 samples, facilitating a wide range of research and informing PHE, DHSC and UK 34 government policy. Here we describe the implementation and use of the Euroimmun 35 anti-SARS-CoV-2 IgG assay and provide an extended evaluation of its performance. 36 We present a markedly improved sensitivity of 91.39% (≥14 days 92.74%, ≥21 days 37 93.59%) compared to our small-scale early study, and a specificity of 98.56%. In 38 addition, we detail extended characteristics of the Euroimmun assay: intra- and inter-39 assay precision, correlation to neutralisation and assay linearity.

40 **2.** Introduction

Since its emergence in Wuhan, Hubei province, China, in late 2019, the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a global pandemic of coronavirus 19 disease (COVID-19). A sobering milestone of three million COVID-19 associated deaths globally was reached on April 16 2021, with a cumulative total of more than 150 million SARS-CoV-2 infections reported worldwide¹. The true scale of SARS-CoV-2 infections globally is likely to be much higher with a substantial number of cases of mild or asymptomatic disease being undetected.

48 The UK's first confirmed case of COVID-19 occurred in a person who had travelled 49 from Hubei province to England on 23 January 2020 and became symptomatic three 50 days later². By the end of February, all four countries of the UK had recorded COVID-51 19 cases and community transmission was established³. Case numbers increased 52 significantly in early March 2020, reaching a total of 6650 laboratory confirmed cases 53 on 23 March⁴ when a national lockdown was implemented. At that time, 54 epidemiological modelling estimated that for every hospitalised COVID-19 case in the 55 UK, there were a further 120-124 infected individuals undetected within the wider 56 community^{4,5}.

Individual laboratories began to investigate the use of in-house tests and it became apparent that the UK would benefit from a nationwide service to identify the prevalence of SARS-CoV-2 cases, including asymptomatic ones. Identification of these cases would be essential to inform government policy decisions; to further scientific understanding about immune response evolution, longevity and correlation to protection; and to estimate the true extent of the UK population's exposure to SARS-CoV-2. Additionally, such a service could address related questions such as the

Page 3 of 36

- 64 performance of alternative SARS-CoV-2 serology assays. However, this work was
- 65 complicated by logistical issues including the availability of relevant test kits that were
- 66 in global demand, and the availability of relevant sample sets to validate new assays.
- 67 Described here is the extended evaluation of the SARS-CoV-2 Euroimmun IgG assay,
- 68 in addition to establishment of a sero-surveillance laboratory using this assay for over
- 69 12 months.

3. Introduction of an anti-SARS-CoV-2 assay

71 The Rare and Imported Pathogens Laboratory (RIPL) at PHE Porton Down was tasked 72 by the UK Government's Department for Health and Social Care (DHSC) with 73 providing a SARS-CoV-2 serology service in support of a national serosurveillance 74 programme. Testing on this scale would require the use of commercial CE-marked 75 serology kits to guarantee the volumes of supply required, the possibility for 76 automation and the necessary quality control of production batches, with our initial 77 focus on an IgG specific assay. An initial market assessment identified only three 78 companies with production kits available. Of these three kits, one targeted antibodies 79 (IgG) against the SARS-CoV-2 spike protein S1 domain, one targeted nucleocapsid, and the third detected antibodies to an unspecified SARS-CoV-2 antigen. Whilst there 80 81 is merit in having assays that target different antigens for the determination of 82 differential antibody responses to SARS-CoV-2 infection, the use of spike was judged 83 to be critical for virus entry to cells and therefore an assay detecting spike protein 84 antibodies seemed the most attractive for initial use. Thus, the Euroimmun assay 85 (targeting the S1 domain) was selected for the urgent operational requirement and to 86 also provide an indication of the immune profile of subjects.

The laboratory had available existing Stratec Biomedical Gemini platforms (Launch Diagnostics, UK) capable of performing automated ELISAs. After initial ELISA optimisation on the Gemini platform, the first samples were tested to generate initial verification and evaluation data, using samples obtained from patients early in infection and with limited or incomplete clinical data through collaborators/hospitals.

On the 30th March 2020, PHE Porton Down went live with a COVID-19 serology 93 94 service for the UK, with an initial capacity of ~800 samples a day. This was later expanded upon addition of two further Gemini platforms, doubling capacity to ~1,600 95 96 samples a day. Just over 12 months later, as of 31st of April 2021, over 160,000 97 samples have been analysed through this assay and workflow, providing answers to key questions about disease spread and the seroprevalence of SARS-CoV-2 infection, 98 99 as well as informing outbreak management activities. To date, the Euroimmun assay 100 has helped to deliver several significant studies for the UK population, covering 101 population serosurveillance⁵; healthcare worker exposure⁶; selection of donors for convalescent plasma⁷⁻¹⁰; characterisation of reference standards; and research to 102 103 determine the durability of the immune response^{6,11,12}.

4. Methods

106 Serum samples

107 Early samples were sourced from collaborating colleagues at PHE Porton Down, PHE 108 Sero-epidemiology Unit Manchester (SEU) and hospitals across England under 109 Material Transfer Agreements (MTAs). These included residual diagnostic sera from 110 SARS-CoV-2 PCR-confirmed samples from hospital in-patients (Guy's and St 111 Thomas' Hospital, The Royal Free, Barnet Hospital and North Hampshire County 112 Hospital, Basingstoke and John Radcliffe Hospital, Oxford), with data available on 113 dates of collection versus onset of disease. Samples collected in Oxford were from 114 individuals consented into 2 studies: Gastro-intestinal illness in Oxford: COVID 115 substudy [Sheffield REC, reference: 16/YH/0247] and Sepsis Immunomics project 116 [Oxford REC C, reference:19/SC/0296]) as described¹³. The large majority of samples 117 were sourced from community cases of SARS-CoV-2 described within the FF100¹⁴ 118 and the PHE serology assay evaluation supporting information¹⁵. Of the Oxford patient 119 cohort, 116 patients were classified as having mild disease, 15 severe, 13 120 asymptomatic, 6 critical and 1 death.

121 To validate the Euroimmun assay (and future serology assays), pre-pandemic 122 negative samples were also sourced to determine specificity. These were obtained 123 from serum banks prior to the COVID-19 outbreak by the Royal College of General 124 Practitioners (RCGP) for routine surveillance schemes and held by PHE SEU.

125 Euroimmun anti-SARS-CoV-2 lgG assay

All testing using the Euroimmun anti-SARS-CoV-2 IgG assay (EI 2606-9601 G,
Euroimmun, Lübeck) was performed using an automated microplate processor
(Stratec Gemini), which automates all aspect of the ELISA from sample dilution,
Page 7 of 36

through to incubations, washing, reading and analysis, according to the manufacturer's instructions for use. Positive and negative kit controls provided by Euroimmun were included with every run, with commercial positive and negative anti-SARS-CoV-2 controls used in parallel (ACCURUN® Anti-SARS-CoV-2 Controls Kit -Series 1000; SeraCare, Gaithersburg) for additional internal quality control. Control values were tracked using a Levy-Jennings plot with Westgard rules applied.

The assay is semi-quantitative, with results expressed as a ratio (index) of the extinction (optical density) of the patient sample (or control) over the extinction of the calibrator. Interpretation of samples were defined according to the manufacturer, with an index value of <0.8 defined as negative, >0.8 to 1.1 defined as indeterminate/borderline and \geq 1.1 interpreted as positive.

140 Linearity and assay variation

To determine the assay linearity, five high titre serum samples were pooled, with twofold dilutions generated, and each dilution was run in replicates of five. Similarly, the NIBSC Anti-SARS-CoV-2 Antibody Diagnostic Calibrant (20/162, NIBSC, Potters Bar) was run in triplicate across 1:5, 1:10, 1:20, 1:50 and 1:100 dilutions. Results from both the pool and NIBSC calibrant were used to determine the linearity of the Euroimmun assay.

The pooled serum samples were additionally used to determine the intra- and inter-assay variation, with five replicates measured each day across five days.

149 Microneutralisation against SARS-CoV-2

150 On a panel of 138 convalescent blood donors that were >28 days post-symptom onset,

151 micro-neutralisation titres against SARS-CoV-2 were determined as previously


described⁷, with neutralisation titres compared against Euroimmun ratio results.Page 8 of 36

5. Extended verification of the Euroimmun assay

154 In our original small-scale evaluation of the Euroimmun assay, reported in June 2020¹⁶ 155 and derived from samples obtained early in the outbreak, 100 PCR-positives samples 156 where the time between sampling and symptom onset was known, were used to 157 determine assay sensitivity, whilst 399 pre-pandemic negatives, 50 serum samples 158 from 2015 seronegative for Borrelia burgdorferi and 50 confounder samples (VZV, 159 EBV, CMV and rheumatoid positive) were used to determine specificity (left panel on 160 Figure 1). Of the positive panel, 100 samples were initially used but this was later 161 reduced to 93, as seven were found to not be PCR-confirmed. Of the positive samples, 162 67/93 tested positive (≥1.1 ratio) on the Euroimmun assay, giving an overall sensitivity 163 of 72.0% (95%CI 61.78-80.86) (Table 1, Figure 3, PHE Original). When analysing 164 only samples taken ≥14 days post-symptom onset, the sensitivity was 73.42% (95%CI 165 62.28-82.73) and at ≥21 days, the sensitivity was 74.67% (95%CI 63.30-84.01)¹⁶.

166 Subsequent to our initial establishment of the serosurveillance service using the 167 Euroimmun assay, further commercial immunoassay platforms and kits were 168 evaluated at the request of the DHSC to inform decisions on the use of high-throughput 169 assays by NHS laboratories for the detection of anti-SARS-CoV-2 antibodies in patient 170 samples^{13,17}. As part of this work, we extended our evaluation of the Euroimmun 171 assay. Due to the limited samples and volumes available for the evaluation of high-172 throughput serology platforms, the panels differed slightly between our initial 173 Euroimmun evaluation and subsequent other commercial assay evaluations performed by PHE Porton Down¹⁵. For the extended evaluation, an additional 592 174 175 PCR-positive samples that were used for the different verifications of the higher-176 throughput platforms (including a head-to-head study¹³) were tested using the 177 Euroimmun anti-SARS-CoV-2 IgG assay.

Page 9 of 36



178

Figure 1: Distribution of evaluation sample results split according to; Left: Original evaluation 179 (n= 692), and Right: Extended evaluation (n=1,799). Dashed lines represent the 180 181 indeterminate range of the Euroimmun assay (ratio or index or s/co ≥ 0.8 and <1.1).

Using this larger panel, the overall sensitivity of the Euroimmun assay was found to be 91.39% (95% CI 89.03% to 93.38%), increasing to 92.74% when using samples with an onset of \geq 14 days (95% CI 90.49% to 94.60%) and 93.59% when using samples with an onset of \geq 21 days (95% CI 91.41% to 95.36%), markedly improved from the original evaluation (**Figure 1, Table 1**, **Figure 3**).

Additionally, the specificity panel was expanded from 499 to 1,114 samples: 303 confounders (CMV, VZV, EBV and Rheumatoid positive samples), 711 pre-pandemic negatives and 100 Lyme disease negative samples from 2015. Using this panel, a specificity of 98.56% was calculated (95%CI 97.65-99.17%, n=1,114), similar to that from the original evaluation (specificity of 99.0%; 95%CI, 97.5-99.7%).

193 Receiver operating characteristic (ROC) analyses showed the highest area under 194 curve (AUC) value was obtained (0.9902) when using samples from the extended 195 evaluation panel with an interval of \geq 21 days from onset of symptoms, whilst the 196 original evaluation showed the lowest AUC (0.9584) (**Table 2**, **Figure 2**).

When examining the temporal distribution of the samples used for each of these
evaluations, there was variation in the interval since disease/symptom onset (Figure
3). Initial evaluation samples gave the highest frequency of reactive samples at 28
days, whilst the extended evaluation showed the highest interval frequency spanning
36-43 days after symptom onset. The majority of convalescent samples with intervals
of <21 days tested positive (25 out of 53 samples).

This variation in interval distribution is reflected by the difference in the sensitivities seen between the two evaluations. **Figure 3** clearly shows that many of the initial PHE evaluation samples was limited in interval range, in part by sample availability, with samples typically taken between 14 to 35 days after symptom onset. This may account

207 for differences in sensitivities with some samples potentially taken too soon after onset 208 of symptoms to identify any detectable antibody response. Conversely, many of the 209 extended evaluation samples, by their nature, were taken from convalescent patients 210 who had had sufficient interval post onset to generate a strong antibody response. 211 However, it should also be noted that no normalisation for sample demographics (for 212 example differences in geographic location, gender, ethnicity or patient age-ranges) 213 had been applied between datasets, so may have occurred and contributed to 214 differences in sensitivity. Analysis of influence of demographic factors between sample 215 sets is beyond the scope of this overview but may be reported in more detail in 216 individual studies. None of our evaluation sets included longitudinal samples from the 217 same patient.

218 Table 1: Sensitivity of the Euroimmun assay from the original PHE evaluation and the

219 extended evaluation described here. Samples giving an indeterminate value are included with 220 negative results.

	All samples			Samples >14 days			Samples >21 days		
Panel	n	sensitivity (%)	95% CI	n	sensitivity (%)	95% CI	n	sensitivity (%)	95% CI
Original ¹⁶	93	72.00	61.78% to 80.86%	83 73.42		62.28% to 82.73%	77	74.67	63.30% to 84.01%
Extended	ended 685 91.39 89.03% to 600 93.38%		92.74	90.49% to 94.60%	579	93.59	91.41% to 95.36%		


221

222 Table 2: ROC analysis values for each of the evaluation panels, with the extended evaluation 223 described here split by total and intervals of \geq 14 and \geq 21 days.

Evaluation	Panel	Area	P value	95% CI	Negatives (incl. confounders)	Positives
Original ¹⁶	Total	0.9584	<0.0001	0.9266 to 0.9902	499	93
	Total	0.9729	<0.0001	0.9631 to 0.9827	1114	685
Extended	≥14 days	0.9886	<0.0001	0.9826 to 0.9946	1114	600
	≥21 days	0.9902	<0.0001	0.9846 to 0.9958	1114	579


224

225



228 *Figure 2:* ROC curves for the Euroimmun assay. Curves are shown for the original (n=592) 229 and extended evaluations (n=1,799), with the extended evaluation further split to show 230 samples with intervals of ≥ 14 (n= 1,714) or ≥ 21 days (n= 1,693) after symptom onset. The 231 green box indicates the MHRA Target Product Profile of serology assays (>98% sensitivity 232 and specificity) at >20 days.





233

234 Figure 3: An overview of samples by interval distribution and evaluation panel, coloured by 235 the Euroimmun assay result. Top: Original evaluation (n=79). Bottom: Extended evaluation 236 (n=624). The sensitivity at an interval of \geq 21 days is included in each graph, in line with the 237 MHRA TPP. Red dashed line indicates 14-day interval, blue dashed line indicates 21-day 238 interval.


240 6. Further assay characteristics

To determine the precision of the Euroimmun assay, five pooled patient samples were used in the absence of an international standard or calibrant at the time to generate a dilution series for linearity and to determine inter- and intra-assay variation, testing five replicates each over five days. The intra-assay and inter-assay variations were found to be <7% and <5% covariance (CV), respectively, indicating high precision when comparing samples across multiple days and replicate samples (Table S1).

247 Similarly, the dilution series was used to determine the linear range of the assay, with 248 an R² value of 0.985 (Figure 4). As more standards became available, the NIBSC 249 Anti-SARS-CoV-2 Antibody Diagnostic Calibrant was serially diluted to generate additional linearity data, providing a similar R² value of 0.955 (Figure 4). From the 250 251 pooled patient sera and the NIBSC calibrant dilutions, the linear range of the assay 252 was determined to lie between index values of 1 and 9. It is noted that the reader 253 configuration on the Gemini platform resulted in strong positive samples that saturated 254 the OD reader and the software assigns an over-read OD value (e.g. 9.999), which 255 can result in an index value of between 25 - 38 depending on the calibrator OD 256 reading. In routine use, the assay was used in a qualitative mode (e.g. 257 positive/negative interpretation respectively) so saturating values were appropriately 258 assigned as positive.


Serology assays that have a strong correlation to neutralising antibody titres are useful surrogates for live virus neutralisation assays, which require significant containment level 3 work. Of the 138 samples that were tested by both neutralisation and the Euroimmun assay, 129 were positive on both, whilst nine were only positive by Euroimmun (**Figure 5**), with seven of these samples giving an index result of 1 - 2

- 264 (close to the indeterminate range). There was a strong correlation between the
- Euroimmun results and the neutralisation titre, with an R of 0.83 ($R^2 = 0.69$).



267

268 Figure 4: Dilutions and linear range of the Euroimmun assay, using pooled patient samples 269 (pool; green) and the 20/162 NIBSC Anti-SARS-CoV-2 Antibody Diagnostic Calibrant 270 (calibrant; red). Results >9 were removed due to saturated OD readings. Results with an index 271 of ≥ 1.1 are considered positive whilst those <0.8 are considered negative, with the 272 indeterminate range (0.8 to 1.1) shown with the dashed black line.



275

<10

Virus neutralisation antibody titre (Log10)


100

1000

Figure 5: Comparison of convalescent blood donor serum samples tested using the Euroimmun anti-SARS-CoV-2 IgG assay (Log10 ratio value) and virus neutralisation antibody titre (Log10). Good correlation (R=0.83, R^2 =0.69) was observed between neutralisation and the Euroimmun assay. Blue line indicates linear model, with 95% confidence interval (grey range). Dashed line indicates the positive cut-off value (\geq 1.1 index), whilst the red square shows the mean of the samples negative by neutralisation, but positive by Euroimmun assay.

7. Use of the Euroimmun assay in the United Kingdom

A number of national and local projects with appropriate ethical approvals have been facilitated through this work and Figure 6 indicates the scope of Euroimmun testing performed by PHE Porton Down between March 2020 to April 2021. Descriptions of some of these projects are highlighted below although more comprehensive analysis is published elsewhere from the respective project groups.



288

Figure 6: An overview of the number of samples tested using the Euroimmun assay at PHE
 Porton Down, with total tests (red-dashed line), spanning March 2020 to April 2021. Colours
 indicate different projects, as described in the text. Projects have since been moved to
 additional platforms as of March 2021.

- As part of a UK serosurveillance scheme, anonymised residual blood donor samples
- from people aged 17-84 from different regions of England were sourced from the NHS
- Blood and Transplant (NHSBT) service to provide additional venous blood samples to
- 297 determine COVID-19 seroprevalence by age and region. This data began prior to other

serosurveillance studies (for example, REACT, ONS) so provided PHE and external
modelling groups with the only source of seroprevalence data for the UK at the time.

300 Approximately 10,000 samples were tested monthly and positivity rate on the 301 Euroimmun assay was determined on a weekly basis, to identify the population-level 302 spread of COVID-19 and inform government decision-making. Data was reported to 303 the Public Health England seroepidemiology steering group, scientific pandemic 304 influenza group on modelling (SPI-M) and DHSC, as well as published in the weekly 305 PHE COVID-19 report⁵. This data helped to determine and understand the scale of 306 asymptomatic spread of COVID-19 within the UK population, allowing PHE, DHSC 307 and modellers to assess age groups and areas that are driving transmission.

In addition to the NHSBT serosurveillance, blood samples were obtained from patients
visiting primary care settings via the Royal College of General Practitioners (RCGP)
Research and Surveillance Centre to determine COVID-19 seroprevalence, with a
total of 24,927 samples tested since March 2020.

312 As part of a collaboration between PHE and NHSBT, convalescent plasma donor 313 samples were tested to determine which donations should be provided for clinical trials 314 assessing the therapeutic effects of convalescent plasma treatment of patients with 315 COVID-19 (NHSBT Conv). The Euroimmun assay was chosen as the results showed a good correlation with neutralisation assays^{7,8}; and donations with a Euroimmun 316 317 serology index result of >9.1 (later revised to 6.0) were shown to be associated with the presence of high neutralising antibody titres of 1:100 or higher^{7,8} and were hence 318 319 selected for trial use. Serological testing in support of this project began in April 2020, 320 with the first patients receiving treatment in the beginning of May as part of the 321 REMAP-CAP trial¹⁰ and subsequently via the RECOVERY trial⁹.

322 Whilst laboratory antibody testing using ELISAs is considered the gold-standard for 323 determining population-level exposure to SARS-CoV-2, additional studies were 324 conducted to determine the feasibility of using lateral flow device antibody tests. On 325 request from DHSC, a study was performed on emergency service workers to evaluate 326 the utility of home antibody testing kits; EDSAB-HOME (Evaluating Detection of 327 SARS-CoV-2 AntiBodies at HOME). Capillary blood samples from >2,500 volunteers 328 were tested on different lateral flow devices and a contemporaneous venous sample was tested on the Euroimmun assay as the reference test¹⁸. 329

330 From the start of the first COVID-19 lockdown in the UK (23 March 2020), the 331 COVIDsortium study (NCT04318314) collected serial samples from a cohort of 731 332 healthcare workers (HCW) with the aim of identifying host and pathogen correlates of 333 protection and pathogenesis in mild/asymptomatic SARS-CoV-2 infection^{19,20}. The 334 Euroimmun assay was used throughout to characterise the serostatus of all study 335 samples which by completion of the final follow-up samples at 1 year, will number 336 more than 13,000 samples. This data helped to define the proportion of this HCW 337 cohort who seroconverted, and was used to monitor the longitudinal antibody 338 response and rate of decline of anti-S1 IgG antibodies⁶ and to investigate the 339 relationship between peak anti-S1 IgG titre and neutralising antibody titre²¹.

In addition, a small project (ESCAPE) began in March 2020 as a mechanism to study
antibody responses to infection. A cohort of Public Health England staff across 4 sites
were recruited, with monthly blood donations taken as a way to understand the kinetics
of antibodies post-infection¹¹.

A collaboration between PHE and Hampshire Hospitals NHS Foundation Trust (HHFT), provided 1885 serial samples from 282 hospital in-patients with acute COVID-

346 19 and 189 serial samples from 50 convalescent HCWs (the PDASH study). All 347 participants had PCR confirmed SARS-CoV-2 infections that ranged from 348 asymptomatic to severe disease. The study used the Euroimmun assay to determine 349 the time to seroconversion and to monitor the longitudinal antibody response in study 350 participants.

351 Other projects included those used specifically for serology assay evaluations 352 conducted by PHE Porton and PHE SEU, smaller research studies, and those 353 conducted by hospitals and colleagues early in the pandemic.

355 **8.** Discussion

The Euroimmun assay has been fundamental to the UK's public health response to COVID-19, with >160,000 samples tested March 2020 to March 2021 (**Figure 6**). This early availability of the assay was key to performing seroprevalence testing in the early stages of the pandemic, informing the policy and legislative responses of PHE, DHSC and the UK Government. It also contributed to our understanding of immune responses during COVID-19 infection and recovery as well as provided real-time (~24 hours) testing of convalescent plasma before being provided for use in clinical trials.

363 Whilst many platforms and assays now exist for the detection of anti-SARS-CoV-2 antibodies (including those evaluated by ourselves²²), there were limited choices 364 365 available at the onset of the pandemic in the UK in March 2020. This highlights the 366 need and basis for pandemic preparedness from an immunology and serology 367 perspective, with the requirement for labs to be able to run high-throughput antibody 368 tests on specimens from patients infected with newly emerging pathogens. Rapid 369 immunology research on a new pathogen enables early understanding of potential 370 immunity and inform early vaccine design. Whilst in-house/research-based assays 371 were available since January 2020, these require significant quality control to ensure 372 consistent diagnosis across batches of samples to ensure consistent sensitivity. 373 Similarly, in-house assays can also suffer from logistical and supply issues for 374 specially manufactured components (recombinant proteins etc). Commercial assays 375 became rapidly available with the spread of SARS-CoV-2 in early 2020, however 376 supply and logistical issues were also evident with the global spread of SARS-CoV-2, 377 so this should be a factor in deciding on assays for serosurveillance.

379 In our original evaluation, we found an overall sensitivity of 72.0% (interval \geq 14 days: 380 73.42%, interval ≥21 days: 74.67%) and a specificity of 99.0% for the Euroimmun 381 assay, whilst the extended evaluation detailed here found an overall sensitivity of 382 91.39% (interval \geq 14 days: 92.74%, interval \geq 21 days: 93.59%) and a specificity of 383 98.56% (Table 1, Figure 2). This data is supported by other studies, which have shown similar high sensitivities of 90%²³, 96%²⁴ and 100%²⁵. The initial evaluation 384 385 suggested a moderate sensitivity for the Euroimmun assay, but this is likely a reflection 386 of the early stages of the pandemic, when serum from patients with confirmed COVID-387 19 were extremely difficult to obtain, disease onset was poorly characterised and little 388 convalescent material was available. This limited the number of samples, as many of 389 the original evaluation samples were obtained from patients with mild disease within 390 the community, so in using these particular samples, this could have resulted in lower 391 sensitivity than anticipated, due to mild infections and resulting in lower antibody 392 responses than those with severe infections or those requiring hospitalisation²⁶. In 393 addition, timing between disease onset and sample date was not fully established for 394 all patient samples, with many taken from patients too early since disease onset, 395 whereby no robust IgG/immunological response is mounted.

Use of an extended sample panel has enabled us to better evaluate the Euroimmun assay. Although the Euroimmun assay showed improved sensitivity in our extended evaluation, in our analysis, it still does not meet the MHRA's Target Product Profile (TPP) of >98% sensitivity recommendation for SARS-CoV-2 serology assays to determine if people have recent infection of SARS-CoV-2²⁷; it does however meet the TPP of >98% specificity.

In addition to improved sensitivity using this extended panel, intra- and inter-assay
variation was found to be low, with covariance of <7% and <5%, respectively. Using
Page 25 of 36

pooled patient samples and the NIBSC diagnostic calibrant, the linear range of the
assay was also determined, enabling semi-quantitative comparisons (Figure 4). Our
results are consistent with other studies that show that only a defined range of the
Euroimmun assay can be used to reliably infer a linear range⁶.

As an anti-spike (S1 domain) antibody ELISA, the Euroimmun assay results also correlate with neutralising antibody titres (R=0.83, R²=0.69) as shown elsewhere^{7,8,28}, suggesting that this assay provides a useful surrogate for virus neutralisation and possible correlation to immune protection (**Figure 5**), without the requirement for containment level 3 facilities and live-virus culture. However, other pseudo-type assays have shown higher correlation²⁸, likely due to the different dynamics between antibody-binding assays and neutralisation-based assays.

415 In addition, as an indirect sandwich ELISA, results are only semi-quantitative and 416 display a maximum reading for optical densities due to reader saturation. In our 417 equipment implementation depending on the calibrator value, max OD values can then 418 result in an index value of between approximately 26 and 38, preventing direct 419 comparisons between samples unless the calibrator values are similar or are within 420 the linear range of the assay, determined here to be between OD values of 1 and 9, 421 (Figure 4). If guantitative results are desired, our recommendation is to dilute samples 422 that are strongly positive to within this range.

423 Notably, of the serology assays evaluated by PHE Porton Down to date²², the 424 Euroimmun assay format does not require the installation of dedicated 425 machinery/specialist equipment, similar to other plate-based ELISA assays. This 426 enables wider use of the assay: it can be utilised in most laboratory settings using 427 automated pipetting platforms (such as the Stratec Gemini), or on the bench with

428 manual pipetting, or within the field since only limited additional laboratory equipment429 such as a plate reader is required.

430 Serology assay selection for different requirements is complex²⁹. This initial 431 programme was principally focused on serosurveillance, further work is now underway 432 at PHE Porton to determine antibody responses induced by vaccination³⁰, vaccine 433 effectiveness³¹, vaccine coverage, variant infection and population spread³², using a 434 combination of serology assays targeting different antigens. With additional assays 435 now available, we have expanded our assays to encompass those with improved 436 sensitivity and specificity, with the capability to change rapidly, enabling better and 437 more accurate analysis of the differing and refined responses to the SARS-CoV-2. 438 Newer assays have enabled us to determine specific protein sub-domain responses 439 (e.g. anti-RBD), as well as using a combination of assays as a mechanism to 440 differentiate between those with previous infection (presence of both anti-spike and 441 anti-nucleocapsid antibodies), those with vaccination and no previous infection 442 (presence of only anti-spike antibodies) and those with previous infection and 443 vaccination (presence of both anti-spike and anti-nucleocapsid antibodies, with 444 significantly higher anti-spike responses as reported elsewhere³⁰).

445 9. Acknowledgements and funding

We thank the many scientists and clinicians that provided PHE Porton with early samples from those with PCR-confirmed SARS-CoV-2 infection in March 2020, including those at Guy's and St Thomas' Hospital, Westminster, Royal Free Hospital, Barnet and North Hampshire County Hospital, Basingstoke. In addition, we thank collaborators from the head-to-head study at Oxford University (Gillian Rodger, Hayleah Pickford, Teresa Street, Kate Dingle, Justine Rudkin, Derrick Crook, David Eyre, Philippa Matthews and Nicole Stoesser).

This project was funded as part of the DHSC serological assay evaluation procedure. AJM and DTS are funded by ISARIC-4C "Medical Research Council (grant MC_PC_19059) as part of the ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC-4C)", COMBAT Consortium, OUH clinical and research staff and patients

458 **10.** Author contributions

ADO and AB wrote the manuscript. AB, DB, ADO, SD'A, TB, AS, MC, PP, AS and RV performed and oversaw the initial evaluation and assay implementation. ADO, AB and SD'A performed the extended assay characterisation. AB, ST, JH, CR and SD'A were responsible for routine testing. EL provided initial evaluation samples and EL & AS facilitated with sourcing samples. AJM and DTS provided additional evaluation samples. AL, HH and MZ were responsible for the microneutralisation work. All authors read and commented on the final manuscript.

466

467

Page 28 of 36

468 11. References

- 469 1. World Health Organization. COVID-19 Weekly Epidemiological Update 22.
 470 World Heal. Organ. 1–3 (2021).
- 471 2. Lillie, P. J. *et al.* Novel coronavirus disease (Covid-19): The first two patients in
 472 the UK with person to person transmission. *Journal of Infection* **80**, 578–606
 473 (2020).
- 474 Chappell, J. G. et al. Retrospective screening of routine respiratory samples 3. 475 revealed undetected community transmission and missed intervention 476 opportunities for SARS-CoV-2 in the United Kingdom. medRxiv 477 2020.08.18.20174623 (2020). doi:10.1101/2020.08.18.20174623
- 478 4. Public Health England. *National COVID-19 surveillance reports*. (2020).
- 479 5. Public Health England. *Public Health England National flu and COVID-19*480 *surveillance reports.*
- 481 6. Manisty, C. *et al.* Time series analysis and mechanistic modelling of
 482 heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2
 483 infection. *EBioMedicine* 65, 103259 (2021).
- 484 7. Harvala, H. *et al.* Convalescent plasma therapy for the treatment of patients with
 485 COVID-19: Assessment of methods available for antibody detection and their
 486 correlation with neutralising antibody levels. *Transfus. Med.* 1–9 (2020).
 487 doi:10.1111/tme.12746
- 488 8. Harvala, H. *et al.* Convalescent plasma treatment for SARS-CoV-2 infection:
 489 analysis of the first 436 donors in England, 22 April to 12 May 2020.
 490 *Eurosurveillance* 25, 2001260 (2020).

Page 29 of 36

- 491 9. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to
- 492 hospital with COVID-19 (RECOVERY): a randomised controlled, open-label,
- 493 platform trial. *Lancet* (2021). doi:10.1016/S0140-6736(21)00897-7
- 494 10. REMAP-CAP Investigators, Estcourt, L. J. Convalescent Plasma in Critically ill
- 495 Patients with Covid-19. *medRxiv* 2021.06.11.21258760 (2021).
- Harris, R. J. *et al.* Serological surveillance of SARS-CoV-2: Six-month trends
 and antibody response in a cohort of public health workers. *J. Infect.* 1–25
 (2021). doi:10.1016/j.jinf.2021.03.015
- Amirthalingam, G. *et al.* Seroprevalence of SARS-CoV-2 among Blood Donors
 and Changes after Introduction of Public Health and Social Measures, London,
 UK. *Emerg. Infect. Dis.* 27, 1795–1801 (2021).
- 502 13. Ainsworth, M. *et al.* Performance characteristics of five immunoassays for
 503 SARS-CoV-2: a head-to-head benchmark comparison. *Lancet Infect. Dis.* 20,
 504 1390–1400 (2020).
- 505 14. Boddington, N. L. *et al.* COVID-19 in Great Britain: Epidemiological and clinical
 506 characteristics of the first few hundred (FF100) cases: A descriptive case series
 507 and case control analysis. *medRxiv* (2020). doi:10.1101/2020.05.18.20086157
- 508 15. Public Health England. Supporting information for the PHE commercial serology
 509 assay evaluations.
- 510 16. Public Health England. Evaluation of the Euroimmun Anti-SARS-CoV-2 ELISA
- 511 (*IgG*) serology assay for the detection of anti-SARS-CoV-2 antibodies. (2020).
- 512 17. Public Health England. *Evaluation of sensitivity and specificity of four* 513 *commercially available SARS-CoV-2 antibody immunoassays.* (2020).

Page 30 of 36

- 514 18. Mulchandani, R. et al. Accuracy of UK Rapid Test Consortium (UK-RTC) 'abC-
- 515 19 Rapid Test' for detection of previous SARS-CoV-2 infection in key workers:
- 516 Test accuracy study. *BMJ* **371**, (2020).
- 517 19. Moon, J. C. *et al.* Healthcare Workers Bioresource: Study outline and baseline
- 518 characteristics of a prospective healthcare worker cohort to study immune
- 519 protection and pathogenesis in COVID-19. *Wellcome Open Res.* **5**, (2020).
- 520 20. Treibel, T. A. *et al.* COVID-19: PCR screening of asymptomatic health-care 521 workers at London hospital. *The Lancet* **395**, 1608–1610 (2020).
- 522 21. Reynolds, C. J. *et al.* Discordant neutralizing antibody and T cell responses in 523 asymptomatic and mild SARS-CoV-2 infection. *Sci. Immunol.* **5**, (2020).
- 524 22. Public Health England. COVID-19: laboratory evaluations of serological assays.
- 525 *GOV.UK* (2021). Available at:
- 526 https://www.gov.uk/government/publications/covid-19-laboratory-evaluations-
- 527 of-serological-assays. (Accessed: 2nd June 2021)
- 528 23. Lassaunière, R. *et al.* Evaluation of nine commercial SARS-CoV-2
 529 immunoassays. *medRxiv* 2020.04.09.20056325 (2020).
 530 doi:10.1101/2020.04.09.20056325
- 531 24. GeurtsvanKessel, C. H. *et al.* An evaluation of COVID-19 serological assays
 532 informs future diagnostics and exposure assessment. *Nat. Commun.* **11**, (2020).
- 533 25. Manalac, J. *et al.* Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and 534 Euroimmun ELISA IgG/IgA assays in a clinical lab. *Clin. Chim. Acta* **510**, 687– 535 690 (2020).
- 536 26. Rijkers, G. *et al.* Differences in antibody kinetics and functionality between Page 31 of 36

- 537 severe and mild severe acute respiratory syndrome Coronavirus 2 infections. *J.*
- 538 Infect. Dis. **222**, 1265–1269 (2020).
- 539 27. MHRA. Target Product Profile: antibody tests to help determine if people have
- 540 recent infection to SARS-CoV-2: Version 2. Available at:
- 541 https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-
- 542 coronavirus-covid-19-work/target-product-profile-antibody-tests-to-help-
- 543 determine-if-people-have-recent-infection-to-sars-cov-2-version-2. (Accessed:
 544 8th April 2021)
- 545 28. Lamikanra, A. *et al.* Comparability of six different immunoassays measuring 546 SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent
- 547 plasma: From utility to prediction. *Transfusion* **61**, 2837–2843 (2021).
- 548 29. Peeling, R. W. *et al.* Serology testing in the COVID-19 pandemic response.
 549 *Lancet Infect. Dis.* **20**, e245–e249 (2020).
- Manisty, C. *et al.* Antibody response to first BNT162b2 dose in previously SARSCoV-2-infected individuals. *Lancet* (2021). doi:10.1016/S0140-6736(21)005018
- 31. Hall, V. J. *et al.* COVID-19 vaccine coverage in health-care workers in England
 and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a
 prospective, multicentre, cohort study. *Lancet (London, England)* 1725–1735
 (2021). doi:10.1016/S0140-6736(21)00790-X
- Whitaker, H. *et al.* Impact of COVID-19 Vaccination Program on Seroprevalence
 in Blood Donors in England, 2021. *J. Infect.* (2021).
 doi:10.1016/j.jinf.2021.04.037

560

561

- 563 **Table S1:** Precision results for the Euroimmun assay using five pooled patient sera.
- 564 Samples were tested in replicates of five over five days. Intra-assay variation was
- 565 <7%, whilst inter-assay variation was <5%

Sample		Day	Day	Day	Day	Day	Inter-	Inter-	Inter-
		1	2	3	4	5	assay Mean	assay SD	assay CV
1	Mean	9.00	8.43	8.59	8.43	8.64			
	SD	0.26	0.13	0.14	0.08	0.13	8.62	0.235	2.724
	CV	2.93	1.59	1.60	0.99	1.50			
2	Mean	6.28	5.95	5.99	6.04	6.12			
	SD	0.11	0.19	0.13	0.16	0.28	6.08	0.132	2.180
	CV	1.69	3.26	2.18	2.64	4.50			
3	Mean	3.72	3.52	3.55	3.67	3.67	+	0.087	2.409
	SD	0.11	0.12	0.04	0.19	0.11	3.62		
	CV	2.84	3.52	1.13	5.17	2.93			
4	Mean	2.07	1.90	1.99	1.99	1.99			
	SD	0.04	0.03	0.06	0.09	0.08	1.99	0.062	3.102
	CV	2.16	1.72	3.12	4.42	4.04			
5	Mean	1.07	0.98	1.02	0.99	1.03			
	SD	0.07	0.01	0.04	0.02	0.07	1.02	0.037	3.620
	CV	6.28	0.55	3.76	2.46	6.60			

566

Table S2: Determination of linear range of EuroImmun assay using serially 568

- 569 diluted pooled patient sera. Pooled serum samples at dilutions of 2, 4 and 8 were
- 570 removed due to OD saturation.

Source	Dilution	Index (mean)	SD
Patient pool	16	8.617	0.235
	32	6.077	0.132
	64	3.624	0.087
	128	1.987	0.062
	256	1.018	0.037
Calibrant	5	7.636	0.793
	10	6.000	0.279
	20	3.673	0.261
	50	1.820	0.100
	100	1.029	0.045
	200	0.614	0.013

571

573 **12.** Appendix 1

574 **PHE Porton Euroimmun testing group** list of authors:

575 Joanna Bacon, Daniel Bailey, Natalie Baker, Jack Bleach, Debbie Blick, Paul Bolton, 576 Abbie Bown, Olivia Carr, Matthew Catton, Melanie Clifford, Tom Coleman, Charlie 577 Cooper, Charlotte Cornbill, Ellie Cross, Mollie Curran-French, Silvia D'Arcangelo, Owen Daykin-Pont, Charlotte Dixon, Phoebe Do Carmo Silva, Ellie Drinkwater, Jackie 578 579 Duggan, Xena Dyball, Jack Easton, Ruth Elderfield, Anaya Ellis, Jenna Furneaux, 580 Harriet Garlant, Barry Gibney, Supriya Gurung, Rachel Halkerston, Robin Hanson, 581 James Hardy, Alexander Hargreaves, Gabrielle Harker, Becky Harrison, Bethany 582 Hicks, Charlotte Hind, Emma Hobbs, James Hogg, Margarita Jablonska, Leah Johal, 583 Caoimhe Kelly, Carensa Knights, Emily Laing, Deborah Lister, Rosa Loffredo, Adam 584 Mabbutt, Bethany Martin, Felicity Marx, Lara Mason, Joanna McGlashan, Debbie 585 McKee, Isobel Miles, Sebastian Millward, Gloria Mongelli, Christopher Moon, Taalia 586 Morgan, Alexandra Morrison, Alexandra Morrison, Anna Moy, Josh Nelthorpe-Cowne, 587 Jack Nevols, Jane Osbourne, Jodie Owen, Ros Packer, Jordan Pascoe, Prem 588 Perumal, Esther Picton-Barlow, Eleanor Porges, Saskia Proud, Deen Qureshi, Anastasia Richardson, April Roberts, Adam Roberts, Amanda Semper, Lauren 589 590 Setterfield, Jennifer Small, Kirstie Speer, Sara Speight, Angela Sweed, Stephen 591 Taylor, Steve Thomas, Sian Tiley, Elizabeth Truelove, Ann Varghese, Richard Vipond, 592 Rosie Watts, Katie West, Clare Wilson, Kate Withycombe, Charlotte Woolley.